Insider Buying: ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Buys $75,000.00 in Stock

ProMIS Neurosciences, Inc. (NASDAQ:PMN) Director Madge K. Shafmaster acquired 60,000 shares of the firm’s stock in a transaction that occurred on Friday, September 20th. The stock was purchased at an average cost of $1.25 per share, for a total transaction of $75,000.00. Following the completion of the purchase, the director now directly owns 68,333 shares of the company’s stock, valued at $85,416.25. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

ProMIS Neurosciences Stock Performance

Shares of PMN stock opened at $1.29 on Friday. ProMIS Neurosciences, Inc. has a fifty-two week low of $0.95 and a fifty-two week high of $3.10. The stock’s fifty day moving average price is $1.38 and its two-hundred day moving average price is $1.71. The company has a market cap of $24.46 million, a PE ratio of -1.74 and a beta of 0.62.

ProMIS Neurosciences (NASDAQ:PMN) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.01. On average, equities analysts predict that ProMIS Neurosciences, Inc. will post -0.24 EPS for the current fiscal year.

ProMIS Neurosciences Company Profile

ProMIS Neurosciences, Inc discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins.